Thus, pharmacological treatment of mood disorders mainly targets serotonergic receptors with a predominance of the 5‐HT1A and 5‐HT2 subtypes, because antidepressant effects, and thus clinical relevance, of other subtypes are not yet fully understood (Artigas et al. This evidence concerns the gene HTR1A and mood disorder.